Oncolytics Biotech Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on developing targeted and cutting-edge therapies, Oncolytics Biotech is committed to advancing the field of oncolytic viruses for the treatment of cancer. The company's research and development efforts aim to provide patients with safe and effective treatments that harness the power of viruses to selectively destroy cancer cells while sparing healthy tissue. By constantly pushing the boundaries of science and seeking collaborations with experts in the field, Oncolytics Biotech strives to improve outcomes and quality of life for patients worldwide.

Oncolytics Biotech Inc is primarily present in Canada and the United States.

Oncolytics Biotech Inc has achieved several significant milestones in its journey. The company successfully received FDA Fast Track Designation for its lead product candidate, REOLYSIN, which is being developed for the treatment of metastatic breast cancer. Oncolytics Biotech also obtained Orphan Drug Designation for REOLYSIN from the FDA for the treatment of pancreatic cancer. Additionally, the company has entered into various strategic collaborations and partnerships to advance its oncology research and development initiatives. These achievements highlight Oncolytics Biotech's commitment to bringing innovative treatments to patients, particularly in the field of cancer therapy.

Oncolytics Biotech Inc is a renowned biotechnology company specializing in the development of innovative cancer therapeutics. Founded in 1998, the company has a rich history and is headquartered in Calgary, Canada. Oncolytics Biotech focuses on harnessing the power of viruses to selectively target and destroy cancer cells without harming healthy tissues. Their flagship product, REOLYSIN®, is a proprietary formulation of the reovirus, which has shown promising results in clinical trials for a variety of cancer types. The company's dedication to research and development has positioned them as a leader in the field of oncolytic viruses, offering hope for effective cancer treatments in the future.

The main competitors of Oncolytics Biotech Inc in the market include companies like Amgen Inc., Roche Holding AG, and Pfizer Inc.

Oncolytics Biotech Inc primarily operates in the biotechnology industry.

The business model of Oncolytics Biotech Inc revolves around developing and commercializing immune-oncology virus-based therapies for the treatment of cancer. By utilizing its proprietary platform technology, the company aims to target and destroy cancer cells without harming normal healthy cells. Oncolytics Biotech's innovative approach involves using genetically modified viruses to selectively infect and replicate within cancer cells, resulting in their destruction. This targeted therapy is designed to stimulate the immune system's response to better fight against cancer cells. Oncolytics Biotech Inc's business model focuses on advancing its therapy candidates through clinical trials, seeking regulatory approvals, and ultimately providing effective treatments to cancer patients.

Коефициентът на цена спрямо печалбата (КЦП) на Oncolytics Biotech е -2,29.

Коефициентът на цена към оборот (KUV) на Oncolytics Biotech е 0.

AlleAktien качественият резултат за Oncolytics Biotech е 3/10.

Приходите не могат да бъдат изчислени в момента за Oncolytics Biotech.

очаквана Oncolytics Biotech печалба е -30,98 млн. CAD.

Oncolytics Biotech is a Canadian company specializing in the development of virotherapeutic treatments for cancer. The company uses specially modified viruses to selectively destroy cancer cells. Oncolytics Biotech operates in the areas of research, development, manufacturing, and marketing. Its main product line is REOLYSIN®, an oncolytic virus that targets and destroys cancer cells in the body. The company aims to expand its portfolio of oncolytic viruses through continuous research and development projects. It collaborates with universities and research institutions worldwide to access important insights and advancements in cancer research. Oncolytics Biotech distributes and markets its biopharmaceutical products primarily through partnerships with pharmaceutical companies both domestically and internationally. The company has also carried out a strategic acquisition of TMG Biosciences to enhance its research capabilities and expand its oncolytic virus portfolio. Overall, Oncolytics Biotech's mission is to defeat cancer through innovative therapeutic approaches, offering a promising new therapy option for cancer patients worldwide.

Oncolytics Biotech разпределя дивидента от 0 CAD на плащания годишно.

Дивидентата за Oncolytics Biotech в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Oncolytics Biotech е CA6823108759.

WKN на Oncolytics Biotech е A2JMW5.

Тикерът на Oncolytics Biotech е ONC.TO.

През последните 12 месеца Oncolytics Biotech изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Oncolytics Biotech да изплати дивиденда в размер на 0 CAD.

Дивидентната доходност на Oncolytics Biotech в момента е .

Oncolytics Biotech изплаща дивидент на тримесечие. Той се разпределя в месеците .

Oncolytics Biotech платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 CAD. Това съответства на дивидентна доходност от 0 %.

Oncolytics Biotech се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Oncolytics Biotech на 25.09.2024 г. в размер на 0 CAD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 25.09.2024 г..

Последното дивидентно плащане беше извършено на 25.09.2024 г..

През година 2023 Oncolytics Biotech изплати 0 CAD под формата на дивиденти.

Дивидентите от Oncolytics Biotech се изплащат в CAD.